Roche Xeloda Combo With Taxotere Approved; Phase IV Dosing Study Planned
Executive Summary
Roche will submit the protocol for a Phase II study comparing three different dose regimens for Xeloda (capecitabine) by January 2002 as one of its postmarketing commitments following the Sept. 7 supplemental approval of the agent for use in combination with Aventis' Taxotere (docetaxel) to treat metastatic breast cancer.